Previous close | 89.95 |
Open | 90.81 |
Bid | 92.15 x 200 |
Ask | 92.34 x 100 |
Day's range | 90.68 - 92.40 |
52-week range | 85.21 - 125.83 |
Volume | |
Avg. volume | 587,959 |
Market cap | 22.229B |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | 22.50 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 June 2022 |
1y target est | N/A |
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.